News Releases

Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2016

BOSTON, Feb. 29, 2016 /PRNewswire/ -- George Elston, Chief Financial Officer of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will present at the 28th Annual ROTH Conference in Dana Point, CA on Monday, March 14, 2016 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) in Salon 5.  Mr. Elston will be joined by Dr. Bridget Martell, the Company's Chief Medical Officer, for a discussion period following the presentation.

Juniper Pharmaceuticals, Inc.

Juniper's presentation will be webcast live via under the 'Investors' tab, or click here.  The webcast will be archived for 90 days at the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health.  The Company is advancing a pipeline of proprietary product candidates that leverage novel intra-vaginal drug delivery technologies.  Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S. Please visit for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals
(917) 673-5775 /

Follow us on LinkedIn   
To receive Juniper's press releases, SEC filings or calendar alerts by email click here.

Logo -

SOURCE Juniper Pharmaceuticals, Inc.